Cargando…

Monoclonal antibodies as anti-infective products: a promising future?

BACKGROUND: The paucity of licensed monoclonal antibodies (mAbs) in the infectious diseases arena strongly contrasts with the ready availability of these therapeutics for use in other conditions. AIMS: This narrative review aims to assess the potential of monoclonal antibody-based interventions for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelfrene, E., Mura, M., Cavaleiro Sanches, A., Cavaleri, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128139/ https://www.ncbi.nlm.nih.gov/pubmed/29715552 http://dx.doi.org/10.1016/j.cmi.2018.04.024

Ejemplares similares

Anti-infective monoclonal antibodies: perils and promise of development
por: Reichert, Janice M., et al.
Publicado: (2006)

Comment on Fauconnier, A. Phage Therapy Regulation: From Night to Dawn
por: Pelfrene, Eric, et al.
Publicado: (2019)

Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight?
por: Pelfrene, Eric, et al.
Publicado: (2021)

Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency
por: Pelfrene, Eric, et al.
Publicado: (2015)

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
por: van Dyck, Christopher H.
Publicado: (2017)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Monoclonal Antibody a Promising Treatment for Depression
por: Akhondzadeh, Shahin
Publicado: (2019)

Precision medicine and monoclonal antibodies: breach of promise?
por: Garattini, Livio, et al.
Publicado: (2019)

Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells
por: Radziejewska, Iwona, et al.
Publicado: (2023)

Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies
por: Wilder, Brandon K., et al.
Publicado: (2022)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
por: Han, Hui-Ju, et al.
Publicado: (2018)

In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
por: Pagant, Silvere, et al.
Publicado: (2021)

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?
por: Longoni, Silvia Stefania, et al.
Publicado: (2021)

Monoclonal Antibodies in Multiple Sclerosis: Present and Future
por: Voge, Natalia V., et al.
Publicado: (2019)

Future of Monoclonal Antibody Therapy in Parkinson’s Disease
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Monoclonal Antibodies for Chronic Pain Treatment: Present and Future
por: Sánchez-Robles, Eva M., et al.
Publicado: (2021)

Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016)

Microbials for the production of monoclonal antibodies and antibody fragments
por: Spadiut, Oliver, et al.
Publicado: (2014)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products()
por: Kelley, Brian, et al.
Publicado: (2022)

Production and characterization of anti-peptide monoclonal antibodies with specificity for staphylococcal enterotoxins A and B
por: Bhatti, A.R., et al.
Publicado: (1999)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

Production of an anti-dermatophyte monoclonal antibody and its application: immunochromatographic detection of dermatophytes
por: Noriki, Sakon, et al.
Publicado: (2016)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
por: Bobrowicz, Malgorzata, et al.
Publicado: (2019)

Production of monoclonal antibodies reactive with ovine eosinophils
por: Sansome, Georgina M, et al.
Publicado: (2007)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Humanization and Characterization of an Anti-Ricin Neutralization Monoclonal Antibody
por: Hu, Wei-Gang, et al.
Publicado: (2012)

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections
por: Sautto, Giuseppe, et al.
Publicado: (2013)

Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy
por: Zhu, Xiaoyi, et al.
Publicado: (2021)

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product
por: Singh, Sanjay Kumar, et al.
Publicado: (2018)

The production and application of non-rodent monoclonal antibodies in veterinary science
por: Groves, D.J., et al.
Publicado: (1989)

Current and Future Applications of Monoclonal Antibodies against Bacteria in Veterinary Medicine
por: SHERMAN, DAVID M., et al.
Publicado: (1986)

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020)

Monoclonal antibody as a potential anti-COVID-19
por: Jahanshahlu, Leila, et al.
Publicado: (2020)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors
por: Andrabi, Raiees, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7gdbmitp7uekidmf2hbin2nvop